ABVC BioPharma Inc. (ABVC) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for ABVC, including 2 press releases and news items and 1 SEC filing. The most recent was published Nov 2, 2026.
Financial highlights
Full financials- Revenue, FY2025
- $296.0K
- Revenue growth
- -41.9%
- Net income, FY2025
- -$7.91M
- Net margin
- -2671.8%
- Cash
- $31.9K
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks18+200%
2026-05-172026-11-08
Mix1490d
- Other9(64%)
- SEC Filings5(36%)
Activity · 52 weeks2717 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PR/C O R R E C T I O N - WallachBeth Capital LLC/In the news release, WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million, issued 02-Nov-2026 by WallachBeth Capital LLC over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows:WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million JERSEY CITY, N.J., Nov. 2, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, an
- PRWallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 MillionJERSEY CITY, N.J., Nov. 2, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ:ABVC), has closed a private placement of original issue discount senior convertible promissory notes ("OID Notes") pursuant to a securities purchase agreement with institutional and other accredited investors, generating aggregate gross proceeds of approximately $3.39 million, before placement agent fees and other offering expenses. The 17.5% OID Notes have an aggregate principal amount of $4,106,060 with a matur
- SECABVC BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form DEF 14A filed by ABVC BioPharma Inc.DEF 14A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form PRER14A filed by ABVC BioPharma Inc.PRER14A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECABVC BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form PRER14A filed by ABVC BioPharma Inc.PRER14A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form 424B4 filed by ABVC BioPharma Inc.424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form 424B4 filed by ABVC BioPharma Inc.424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form 424B4 filed by ABVC BioPharma Inc.424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form 424B4 filed by ABVC BioPharma Inc.424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form PRER14A filed by ABVC BioPharma Inc.PRER14A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form 10-Q filed by ABVC BioPharma Inc.10-Q - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECAmendment: ABVC BioPharma Inc. filed SEC Form 8-K: Other Events8-K/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECABVC BioPharma Inc. filed SEC Form 8-K: Other Events8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form PRE 14A filed by ABVC BioPharma Inc.PRE 14A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECABVC BioPharma Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form 10-Q filed by ABVC BioPharma Inc.10-Q - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form NT 10-Q filed by ABVC BioPharma Inc.NT 10-Q - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form POS AM filed by ABVC BioPharma Inc.POS AM - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECABVC BioPharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form DEF 14A filed by ABVC BioPharma Inc.DEF 14A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECAmendment: SEC Form 10-Q/A filed by ABVC BioPharma Inc.10-Q/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECSEC Form 10-K filed by ABVC BioPharma Inc.10-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
- SECABVC BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
ABVC FAQ
9 questionsWhat does ABVC BioPharma Inc. do?
American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It...What is the latest news on ABVC?
In the last 30 days Quantisnow tracked 3 wire items for ABVC: 2 press releases and news items and 1 SEC filing. The most recent was published on November 2, 2026.What is ABVC revenue?
ABVC BioPharma Inc. (ABVC) reported $296.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 41.9% from the year before.Is ABVC profitable?
No. ABVC BioPharma Inc. reported a net loss of $7.91M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ABVC have?
ABVC BioPharma Inc. reported $31.9K in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ABVC stock trade?
ABVC BioPharma Inc. (ABVC) is listed on NASDAQ.What sector and industry is ABVC in?
ABVC BioPharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to ABVC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ABVC side-by-side with any of them on Quantisnow.How can I track ABVC on Quantisnow?
Quantisnow aggregates ABVC BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABVC to receive live email and push alerts on every new disclosure.